Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This is a single-center, open, randomized, controlled phase 2 clinical trial designed to
compare low-dose-bevacizumab and pemetrexed with TPC in metastatic HER2-negative breast
cancer patients after failure of taxanes and anthracycline-containing regimens.